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In addition, the supervising staff in hospital kitchens
have been shown how to carry out the test and have
found it most useful in the supervision of the cleaning of
utensils, equipment and working surfaces.
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Diabetogenic Drugs •ID the Vervet Monkey
J. A. M. WHITE, M. C. BOLSTRIDGE, H. J. DOWNING, E. H. HELM, H. J. KLOMFASS
SUMMARY
Alloxan and streptozotocin were used to cause beta cell
lysis in vervet monkeys used as recipient models for
pancreatic allografts.
Tests were performed on these animals to evaluate the
effect of the drugs on carbohydrate metabolism. Strepto-
zotocin is preferred as the drug of choice in creating a
non-pancreatectomised hyperglycaemic recipient for
pancreatic allografting.
S. Afr. Med. l., 48, 273 (1974).
The first vascularised allograft was performed on the dog
in 1957.' Most of the subsequent work in this field has been
carried out in this species.'" Kelly et al: and Lillehei and
others' have carried out simultaneous renal and pancreatic
allografting on patients with juvenile onset diabetes and
diabetic nephropathy. Marks et al.' have indicated the
importance of late islet cell deficiency as a common cause
of death in intractable chronic pancreatitis. The final role
of vascularised pancreatic allografts remains to be assessed,
but initial experience has suggested that the method can be
employed to reverse at least some of the effects of the
islet deficiency. The anatomy of the pancreas is similar in
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man and in the other higher primates. The vervet monkey
(Cercopithecus pygerythl'lls F. Cuvier) has been chosen as
a non-human model because it is readily available in Natal
and has been the subject of immunological study in this
region. The viability of a pancreatic allograft may be
assessed by the capacity of the graft to produce insulin.
Total pancreatectomy before grafting is laborious. hazar-
dous and removes all exocrine pancreatic tissue. Selective
destruction of the beta cells of the islets of the recipient
has therefore been preferred as a method of providing a
'diabetic' model in a small non-human primate.
Two drugs are available for this purpose. The diabeto-
genic action of alloxan in rats has been reported.'" Strepto-
zotocin has been evaluated in a wider range of animals, in-
cluding non-human primates:'" Neither has been evaluated
in the vervet monkey. This study has been designed to
evaluate their diabetogenic action in this species. Plasma
glucose levels in fasting animals, urine volumes, pH, and
urinary glucose levels were determined, and glucose
tolerance tests have been carried out. The glucose tolerance
tests were carried out as subdiabetic animals have normal
fasting glucose levels but show impaired carbohydrate
metabolism when challenged with a glucose load.
MATERIALS AND METHODS
Animals and Diet
Ten healthy adult vervet monkeys of mass 2,0 kg to
5,15 kg were housed in individual metabolic cages. For
a month before the tests they were given a standardised
diet consisting of approximately 70"" carbohydrate and
30"0 protein. Enough fresh fruit and vegetables were in-
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vitamins. Such a standardised diet is essential, as the results
of the glucose tolerance tests can be influenced by a re-
stricted carbohydrate intake."
Tests on Normal Monkeys
Before the administration of the diabetogenic drugs,
daily fasting plasma glucose concentrations were deter-
mined. Glucose tolerance tests were performed on the
monkeys to establish the normal carbohydrate metabolism.
Saline control tests substituting isotonic saline for the
glucose load were performed on 2 monkeys.
To establish normal urine values, 24-hour urine volume
was noted. Samples were tested for protein, blood and pH,
using Hema-Combistix (Ames Laboratories), and for
glucose by means of Clinitest tablets (Ames Laboratories),
using the 'two-drop' method."
Glucose Tolerance Tests
ExperirnnentalPTocedure
After administration of these drugs to 2 groups of
monkeys the following tests were performed: fasting
plasma glucose determinations for 4 days and 3 times a
week thereafter, 24-hour urine volume monitored as pre-
viously described at the preceding intervals mentioned,
and glucose tolerance tests on the surviving monkeys after
40 - 45 days.
RESULTS
The daily fasting plasma glucose concentration of the
animals treated with alloxan and streptozotocin are shown
in Table I. In the alloxan group there was a mean increase
of 65 mg/lOO ml on day 1, and thereafter the glucose
TABLE I. DAILY FASTING PLASMA GLUCOSE CONCEN-
TRATIONS (mg/l00 ml) OF ANIMALS TREATED WITH
ALLOXAN AND STREPTOZOTOCIN
• Animals died.
concentration rose by 213 mg/lOO ml on day 2 and con-
tinued to rise, reaching a peak of 445 mg/lOO ml on the
7th day. The concentration then dropped and became
stable at 155 and 160 mg/lOO ml after Jay 18. All the
animals receiving streptozotocin became hypoglycaemic on
day 1 after injection. The mean increase on day 2 was
370 mg/lOO ml, after which the glucose concentration
dropped. Hyperglycaemic stabilisation occurred after 14
days. There was variation in response to both drugs, but
this variation was greater in the group treated with allo-
xan, as can be seen from the standard deviations. In this
group, animal 268 failed to show marked hyperglycaemia
(maximum plasma glucose concentration was 150 mg/
100 ml on day 7) while monkey 216 died on day 7 with a
plasma glucose concentration of 1 135 mg/lOO mJ. 'The
mean volume of urine excreted in a 24-hour period in
normal animals was 215 ml, and there was no glucose,
blood or protein present. The pH range was 7 - 8.
The glucose tolerance tests were performed in the
following manner. After an overnight fast the animals were
anaesthetised with an intramuscular injection of 15 mg/kg
of ketamine hydrochloride (Ketalar; Parke-Davis).
Muscular spasm was counteracted by intravenous admini-
stration of 2,5 mg/kg of a benzodiazepin derivative
(Valium; Roche). During the preliminary studies it was
found that stress before anaesthesia resulted in elevated
fasting blood glucose levels and abnormal glucose tolerance
curves. Stress was therefore reduced to a minimum by the
use of 'crush' metabolic cages which enable the experi-
menter to quickly immobilise the animals against the front
of the cage where they can be easily injected.
A polyethylene catheter was inserted into the femoral
vein via the saphenous vein. A control blood sample was
taken and 2000 mg glucose in a 40% solution was in-
jected via the catheter.
The glucose load was not adjusted to the weight of the
animal, since this has been found to be unnecessary."
Blood samples were taken at 5-min intervals for 30 min,
and at lO-min intervals for a further 30 min. The blood
samples were taken into tubes containing a few crystals
of sodium fluoride and the glucose concentration was
determined on a Beckman analyser using the enzyme
glucose oxidase.
Diabetogenic Drugs
A mixture of 100 g streptozotocin (Upjohn) and 96 g
citric acid was dissolved in sufficient sterile apyrogenic
water to make a solution containing 10 mg/ml of strepto-
zotocin. Sodium hydroxide was added to pH 4,5. 11 The
solution was immediately injected intravenously into 5
monkeys in a dose of 60 mg/kg. _
A 10% solution of alloxan' (British Drug Houses) was
made up to pH 5 in apyrogenic water. After sterile filtra-
tion the alloxan solution was immediately administered by






Monkey 0 2 3 4 7 11
169 65 206 194 248 342 239 195
193 69 74 224 318 354 255 290
167 72 193 456 570 582* -
216 75 112 786 500 648 1135*
268 74 98 86 127 129 150 132
Mean 71 136 349 353 411 445 206
SO 4 53 249 162 185 401 65
212 63 23 405 411 345 270 285
183 79 19 312 384 276 195 201
262 75 23 369 354 477* -
263 65 53 485 396 264 340 219
257 65 50 450 306 225 240 321
Mean 69 34 404 370 317 261 257
SO 6 15 61 37 89 53 49
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Fig. 1. :Mean plasma glucose concentrations in normal,
alloxan- and streptozotocin-treated monkeys before and
after intravenous infusion of glucose, compared with
saline controls.
in the streptozotocin and alloxan groups respectively. There
was no significant difference between these figures. The
mean 60-min value of the streptozotocin group was
85 mg/lOO ml above the mean fasting concentration and
that of the alloxan group was elevated by 27 mg/IOO m!'
The glucose tolerance curve of the animals· treated with
streptozotocin was significantly different from that of the
normal animals at all sample times except at the 5-min
time. The alloxan group did not differ significantly from
the streptozotocin group, and both were significantly dif-
ferent from the normal group after the 20-min sample.
Animal 268 showed impaired tolerance. with the 60-min
plasma glucose concentration being 88 mg/ tOO ml above
its fasting value.
The results of postmortem examinations which were
performed on the animals that died were similar for both
groups. All the animals had very little or no subcutaneous
fat. The kidneys appeared to be normal, the liver was more
friable than normal, and areas of fatty infiltration were



















In the alloxan-treated animals the volume of urine ex-
creted was below normal on day I and subsequently in-
creased, reaching a maximum on day 4 with a mean of
298 ml. The animals with a high plasma glucose con-
centration excreted between 330 and 750 ml on days 3 and
4. The others showed no marked polyuria. The mean urine
volume of the animals treated with streptozotocin was well
above normal on all days and the maximum was 620 ml
on day 3.
In both groups of animals 2 had traces of glucose in the
urine on day 1 and all (except alloxan animal 268) exhi-
bited marked glucosuria on the subsequent days. Animal
268, which failed to become hyperglycaemic, excreted be-
tween 30 and 80 ml urine per day, and no traces of glucose
were present at any stage. A slight amount of blood was
excreted by this animal on day 2, while the other animals
treated with alloxan showed no trace of haematuria.
Protein was present in the urine of 3 of the alloxan
group monkeys on days 1 and 2, and from day 8 onwards.
In the streptozotocin group a lot of protein was present
between days 7 - 11. Before that traces occurred in the
urine of 1 or 2 animals. After day 11 no protein was
excreted.
The urine of the animals which received alloxan showed
a wide range of pH (from 5 to 8) until day 4, when pH was
7 - 8. The urine was acidic (pH 5 - 6) in all the animals on
day 8, after which the pH returned to normal. In the
streptozotocin group the pH of the urine was normal
except between days 3 and 7 when it became acidic (pH 5).
The results of the glucose tolerance tests are shown in
Table II and Fig. 1. The plasma glucose concentration in
the normal animals returned to a fasting level within 40
min, and the mean 60-min value was 34 mg/l00 ml below
the mean fasting concentration, as was that of the saline
controls. There was no significant difference between the
rate of glucose clearance in the heavy animals (mass>5 kg)
and in the lighter animals (mass<3,4 kg), although the
plasma glucose concentration in the heavy animals tended
to return to fasting level sooner. Five minutes after the
administration of the glucose load, the plasma glucose con-
centration had risen by a mean of 225 mg/l00 ml in the
normal animals, and by 184 mg/100 ml and 128 mg/IOO ml
TABLE 11. MEAN PLASMA GLUCOSE CONCENTRATIONS (mg/l00 ml) IN NORMAL, ALLOXAN- AND
STREPTOZOTOCIN-TREATED MONKEYS BEFORE AND AFTER INTRAVENOUS INFUSION OF GLUCOSE,
COMPARED WITH SALINE CONTROLS
Sample times (min)
Fast 5 10 15 20 25 30 40 50 60
Saline 99 86 75 80 75 73 81 79 72 69
Normal mean 94 319 208 185 148 131 116 92 75 60
SO 18 76 26 22 25 27 31 32 32 26
Strep. mean 188* 372 322t 315t 303* 307' 289' 281' 273' 273'
SO 28 92 47 52 45 60 50 60 66 60
Alloxan mean 140 268 243 236 240t 225t 219t 206* 186* 167*
SO 36 37 40 44 50 43 46 34 26 28
* Significantly different from normal group (P<O.OOl).
t Significantly different from normal group (P<O.Ol).
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DISCUSSION
The hypoglycaemic phase after the administration of strep·
tozotocin is similar to that observed by lunod et al.]· The
early hyperglycaemic phase was not noticed, as blood
samples were not taken before 24 hours. The triphasic
pattern reported by Dunn" was not observed, probably
because of the sampling times selected in the experiment.
The range of response in the animals treated with strep-
tozotocin was wider than that obtained in rats," but was
more constant than that obtained by Pitkin and Reynolds"
in rhesus monkeys. This variation and that of the animals
treated with alloxan, which was greater, are probably due
to the differing genetic constitutions of the animals and
their adjustment to captivity. These variables are not found
in inbred strains of laboratory animals.
Major changes in sensitivity to alloxan due to nutri-
tional status have been reported,]· but this is an unlikely
explanation as all animals were given a standardised diet,
and all received alloxan at the same time after an over-
night fast.
Streptozotocin appears to produce more reproducible
results than alloxan as the range of response was more
limited than it was in the animals given alloxan. In the
streptozotocin group the hypoglycaemic phase is probably
caused by the rapid release of insulin due to permanent
damage to the beta cells of the pancreas. The blood
glucose reached a maximum on day 2, after which it
dropped, becoming stable after 14 days. This suggests that
the remaining beta cells were able to overproduce to com-
pensate for the loss of the other insulin-producing cells.
As the maximum glucose concentration in the alloxan
group only occurred on day 8, it seems likely that the 2
diabetogenic drugs may destroy the beta cells by different
mechanisms despite the common end-result.'·
Contrary to the report that streptozotocin does not
cause acidosis in rats,'· in the present study the urine of
the animals became increasingly acidic. This agrees with
the findings of Pitkin and Reynolds." There was no
difference between the effect of the 2 drugs on the pH of
the urine, and renal damage appears to have occurred in
both groups, as the animals excreted small amounts of
blood and protein.
The reason that the 60·min glucose concentration of
the normal animals during the glucose tolerance tests was
below the fasting value, is probably that the fasting values
were elevated owing to stress. Although this was reduced to
a minimum, the animals became excited before being
injected, and this would raise the fasting glucose con-
centration. The elevated 60-min values of the animals
treated with alloxan and streptozotocin show that the
animals had impaired carbohydrate tolerance. Monkey
268 responded abnormally to the glucose load, emphasising
the need for the glucose tolerance test in studies of this
nature. The insignificant difference between the results of
the heavy and light monkeys supports the view of MacLean
and de Wesselow,'" who found that it was unnecessary to
adjust the glucose load.
On the basis of these findings it would appear that strep-
tozotocin is the more satisfactory drug for inducing dia-
betes in vervet monkeys, but more needs to be known
about the mode of action of both drugs in this species.
Such investigations are currently being undertaken.
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